Literature DB >> 27645105

Who detects melanoma? Impact of detection patterns on characteristics and prognosis of patients with melanoma.

José Antonio Avilés-Izquierdo1, Irene Molina-López2, Enrique Rodríguez-Lomba2, Ivan Marquez-Rodas3, Ricardo Suarez-Fernandez2, Pablo Lazaro-Ochaita2.   

Abstract

BACKGROUND: Despite the importance of early diagnosis, patients with cutaneous melanoma often seek consultation at advanced stages of the disease. The impact on prognosis according to who first detects the primary tumor has not been established.
OBJECTIVE: This study aims to determine who first detects melanoma, the reasons that patients with melanoma consult a doctor, and the impact of detection patterns on the characteristics and prognosis of melanoma.
METHODS: Seven hundred eighty-three patients with cutaneous melanoma who were diagnosed between 1996 and 2012 were included. Associations between who first noticed the melanoma (ie, self-detected, relatives, health care workers, or dermatologists), epidemiology, clinical presentation, histology, and patient outcomes were analyzed.
RESULTS: Most melanomas were self-detected (53%). Among these patients, 32% consulted because of bleeding, itching/pain, or nodule enlargement. There were more melanomas self-detected among women than among men, and these had a better prognosis. Men had significantly more melanomas on non-easily visible locations than women did. Among melanomas noticed by dermatologists, 80% were incidental findings. Self-detected melanomas were thicker and more frequently ulcerated, developed metastases more often, and were associated with more melanoma-related deaths.
CONCLUSIONS: Patients with melanomas detected by dermatologists had better prognoses than patients with self-detected melanomas. Patients with melanomas that were self-detected by women had better prognoses than those that were self-detected by men, especially for patients >70 years of age. This group might therefore be a logical target for melanoma detection education.
Copyright © 2016 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cutaneous melanoma; diagnosis; epidemiology; gender; pattern detection; prognosis; skin cancer; tumor thickness

Mesh:

Year:  2016        PMID: 27645105     DOI: 10.1016/j.jaad.2016.07.009

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  18 in total

1.  Cancer survival in adult patients in Spain. Results from nine population-based cancer registries.

Authors:  M D Chirlaque; D Salmerón; J Galceran; A Ameijide; A Mateos; A Torrella; R Jiménez; N Larrañaga; R Marcos-Gragera; E Ardanaz; M Sant; P Minicozzi; C Navarro; M J Sánchez
Journal:  Clin Transl Oncol       Date:  2017-07-17       Impact factor: 3.405

2.  Why do patients with thick melanoma have different outcomes? A retrospective epidemiological and survival analysis.

Authors:  E Rodríguez-Lomba; I Marquez-Rodas; E Mercader-Cidoncha; R Suárez-Fernández; J A Avilés-Izquierdo
Journal:  Clin Transl Oncol       Date:  2017-03-01       Impact factor: 3.405

3.  ["Indolent" pigmented skin tumor for more than 20 years].

Authors:  C A F Diernaes; J E F Diernaes; S Haase; A Blum
Journal:  Hautarzt       Date:  2017-10       Impact factor: 0.751

4.  Who Detects Skin Cancer? Factors Associated With the Suspicion of Malignancy in Patients With Skin Tumors.

Authors:  Alberto Conde-Taboada; Laura Croissier; Elena González-Guerra; Lucía Campos; Beatriz Aranegui; Eduardo López-Bran
Journal:  Dermatol Pract Concept       Date:  2019-12-31

5.  A cancer registry-based analysis on the non-white populations reveals a critical role of the female sex in early-onset melanoma.

Authors:  Tze-An Yuan; Frank Meyskens; Feng Liu-Smith
Journal:  Cancer Causes Control       Date:  2018-03-09       Impact factor: 2.506

6.  Effects of COVID-19 Lockdown on Tumour Burden of Melanoma and Cutaneous Squamous Cell Carcinoma.

Authors:  Antonio Tejera-Vaquerizo; Sabela Paradela; Agusti Toll; Jorge Santos-Juanes; Ane Jaka; Alba López; Javier Cañueto; Àlvaro Bernal; Isabel Villegas-Romero; Carla Ferrándiz-Pulido; Héctor Perandones; David Moreno-Ramírez; Carolina Domínguez-Mahamud; Rafael Salido-Vallejo; Onofre Sanmartin; Francisco M Almazán-Fernández; Pedro Rodríguez-Jiménez; José Bañuls; Sebastian Podlipnik; Alejandra Sandoval-Clavijo; Aram Boada; Beatriz García-Bracamonte; Sara Palencia; David Revilla-Nevreda; Enara Reola-Ramírez; María Del Carmen Gómez-Mateo; Mario Linares-Barrios; David Jiménez-Gallo; Carlos González-Cruz; Elia Samaniego; María Navedo-de Las Heras; Rosa Taberner; Teresa Ródenas-Herranz; Carmen García-Donoso; Susana Puig; Eduardo Nagore
Journal:  Acta Derm Venereol       Date:  2021-08-25       Impact factor: 3.875

7.  Multiple Primary Melanomas: Retrospective Review in a Tertiary Care Hospital.

Authors:  Rodolfo David Palacios-Diaz; Blanca de Unamuno-Bustos; Carlos Abril-Pérez; Mónica Pozuelo-Ruiz; Javier Sánchez-Arraez; Ignacio Torres-Navarro; Rafael Botella-Estrada
Journal:  J Clin Med       Date:  2022-04-22       Impact factor: 4.964

8.  Oridonin inhibits migration, invasion, adhesion and TGF-β1-induced epithelial-mesenchymal transition of melanoma cells by inhibiting the activity of PI3K/Akt/GSK-3β signaling pathway.

Authors:  Chun-Yu Li; Qi Wang; Shen Shen; Xiao-Lu Wei; Guo-Xia Li
Journal:  Oncol Lett       Date:  2017-11-15       Impact factor: 2.967

9.  Early Phase of Primary Melanoma Growth from the Patient Point of view: A Prospective Cross Sectional Study on Melanoma over 1 mm in Thickness.

Authors:  Nausicaa Malissen; Safia Abed; Nicolas Macagno; Florent Amatore; Anderson Loundou; Florent Grange; Caroline Gaudy-Marqueste; Jean-Jacques Grob
Journal:  Acta Derm Venereol       Date:  2020-07-28       Impact factor: 3.875

10.  Development of a Prediction Model for Patients at Risk of Incidental Skin Cancer: A Multicentre Prospective Study.

Authors:  Álvaro Iglesias-Puzas; Alberto Conde-Taboada; Beatriz Aranegui-Arteaga; Eduardo López-Bran
Journal:  Acta Derm Venereol       Date:  2021-07-13       Impact factor: 3.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.